Caedo Oncology
Caedo Oncology is dedicated to creating improved treatment options for cancer patients through unique immunotherapy opportunities. The company develops new strategies for monoclonal antibody-based therapy, focusing on activation of distinctive pathways for cell death in cancer cells. Established in November 2020 based on research at Oslo University Hospital, Caedo aims to be a leader in cancer immunotherapy by leveraging proprietary monoclonal antibodies that trigger programmed cell death in cancer cells, offering a potentially more selective and effective treatment approach.
Industries
Nr. of Employees
small (1-50)
Products
Bifunctional anti-CD47 monoclonal antibody
A therapeutic monoclonal antibody candidate that combines blockade of CD47–SIRPα interactions with direct, rapid induction of programmed cell death in responsive cancer cells; designed to target unique epitopes and exhibit high-affinity CD47 binding.
Bifunctional anti-CD47 monoclonal antibody
A therapeutic monoclonal antibody candidate that combines blockade of CD47–SIRPα interactions with direct, rapid induction of programmed cell death in responsive cancer cells; designed to target unique epitopes and exhibit high-affinity CD47 binding.
Services
Collaborative research and translational partnerships to advance monoclonal antibody therapeutics from academic discovery through preclinical evaluation.
Collaborative research and translational partnerships to advance monoclonal antibody therapeutics from academic discovery through preclinical evaluation.
Expertise Areas
- Monoclonal antibody discovery
- Antibody engineering and optimization
- Cancer immunotherapy mechanisms
- Preclinical in vivo pharmacology
Key Technologies
- Hybridoma technology
- Monoclonal antibody therapeutics
- Epitope mapping and characterization
- Checkpoint inhibition targeting (SIRPα–CD47)